Synergistic estrogenic effects of Fusarium and Alternaria mycotoxins in vitro.

Mycotoxins are toxic secondary metabolites formed by various fungal species that are found as natural contaminants in food. This very heterogeneous group of compounds triggers multiple toxic mechanisms, including endocrine disruptive potential. Current risk assessment of mycotoxins, as for most chemical substances, is based on the effects of single compounds. However, concern on a potential enhancement of risks by interactions of single substances in naturally occurring mixtures has greatly increased recently. In this study, the combinatory effects of three mycoestrogens were investigated in detail. This includes the endocrine disruptors zearalenone (ZEN) and α-zearalenol (α-ZEL) produced by Fusarium fungi and alternariol (AOH), a cytotoxic and estrogenic mycotoxin formed by Alternaria species. For evaluation of effects, estrogen-dependent activation of alkaline phosphatase (AlP) and cell proliferation were tested in the adenocarcinoma cell line Ishikawa. The estrogenic potential varied among the single substances. Half maximum effect concentrations (EC50) for AlP activation were evaluated for α-ZEL, ZEN and AOH as 37 pM, 562 pM and 995 nM, respectively. All three mycotoxins were found to act as partial agonists. The majority of binary combinations, even at very low concentrations in the case of α-ZEL, showed strong synergism in the AlP assay. These potentiating phenomena of mycotoxin mixtures highlight the urgent need to incorporate combinatory effects into future risk assessment, especially when endocrine disruptors are involved. To the best of our knowledge, this study presents the first investigation on synergistic effects of mycoestrogens.

Changes in intramuscular fat, fatty acid profile and cholesterol content induced by zeranol implantation strategy in hair lambs.

BACKGROUND: The effect of zeranol implantation strategy on intramuscular fat, fatty acid profile and cholesterol content of the longissimus dorsi muscle of hair lambs was studied. Four treatments were tested: C, control group; Z12, 12 mg zeranol; Z24, 24 mg zeranol in a single application; and RZ12, 12 mg zeranol given twice. One-way analysis of variance was employed to estimate the effect of treatments (P < 0.05). To separate the effect of the mean, orthogonal contrasts were tested: C1, C versus Z12 + Z24 + RZ12; C2, Z12 versus Z24 + RZ12; and C3, Z24 versus RZ12. RESULTS: A decrease (P < 0.05) in intramuscular fat content was observed from implanting (C1 effect) and zeranol reimplantation (C3 effect). Implanted lambs exhibited an increase (P < 0.05) in monounsaturated fatty acids compared with control group (40.60% versus 35.35%). All contrasts were significant for the sum of n-6 and n-3, with values lower (P < 0.05) in the control (n-6: 0.84% and n-3: 1.38%) and higher in the RZ12 treatment (n-6: 7.55% and n-3: 14.9%). Cholesterol decreased by 78% with implantation and increasing the dose. CONCLUSION: The results indicate that it is possible to induce favorable changes in the fatty acid profile and cholesterol content using a zeranol implantation strategy on hair lambs.

The mycoestrogen zeranol at high dosage antagonizes transient receptor potential channel activities in 3T3 L1 cells.

Recent findings have revealed that exposure to environmental contaminants may result in obesity and pose a health threat to the general public. As the activity of transient receptor potential channels (TRPs) plays a permissive role in adipogenesis, the interactions between TRPs and some food pollutants, i.e. bisphenol A, di (2-ethylhexyl) phthalate, zearalenone, and zeranol at 10 µM were investigated in the present study. TRP-V1,-V3, -C4 and -C6 are reported to be differentially expressed in the adipocyte differentiation, and immunoblotting was performed to quantify changes in these TRPs affected by the pollutants. Our result indicated that the mycoestrogen zeranol or α-zearalanol suppressed the expression of the V1 and C6 isoforms. Subsequently, confocal microscopy was used to measure the calcium inflow repressed by zeranol from 0.1 µM to 10 µM. Oil Red O staining was used to determine the differentiation of 3T3 L1 preadipocytes. Zeranol could suppress the expression of TRP-V1 and -C6 protein and inhibit the associated flow of calcium into the cytosol of 3T3 L1 cells. Its IC50 value for inhibiting calcium inflow stimulated by 40 µM capsaicin or 10 µM GSK1702934A was estimated to be around 6 µM. Reduced TRP-V1 or -C6 activity might result in promoting adipogenesis. In conclusion, this study demonstrated that zeranol could potentiate fat cell differentiation through antagonizing TRP-V1 and -C6 activities.

Resorcylic acid lactones in urine samples of slaughtered animals resulting from potential feed contamination with zearalenone.

Resorcylic Acid Lactones, including zeranol, anabolics listed in the group A4 of Directive 96/23/EC, are banned in Europe for use in animals since 1985. Zeranol, after administration to animals, is metabolized to taleranol and zearalanone. It can also naturally occur in the urine due to conversion of zearalenone that may be present in animal feed. In 2010-2017, in Poland, 7746 animal samples were tested for zeranol residues within the official monitoring program. In 13, zeranol was detected after screening. Re-examinations confirmed resorcylic acid lactones in six samples. The recommendations state that only the presence of zeranol and/or taleranol gives the basis for non-compliance. Confirmation should cover the entire profile of six resorcylic acid lactones. In case of detection, the relationship ratio should be verified. Following the proposed criteria, it could be concluded that zeranol detected in urine samples in Poland originated from contamination of feed with mycotoxin, not from illegal use.

Effects of Zeranol upon luteal maintenance and fetal development in peripubertal gilts.

Eighty gilts were utilized to determine whether zeranol implants could maintain hCG-induced corpora lutea (CL) in peripubertal gilts and to examine the effects of a Zeranol implant on fetal development. Crossbred gilts (171+/-0.3 days of age, 109.1+1.4 kg) were blocked by weight and ancestry to control (n=40) or treatment (n=40) groups. To induce ovulation and CL maintenance, treated gilts received 500 IU of hCG i.m. and a Zeranol ear implant (Ralgro, 36 mg; day 0). All gilts were checked once daily for estrus with a mature boar from days 3-58 of the experiment. On day 42, treated gilts received two 10 mg injections of Lutalyse (PGF(2)alpha) spaced 6 h apart. Treated gilts not displaying estrus within 7 days of PGF(2)alpha received two additional 10 mg of PGF(2)alpha spaced 6 h apart on day 49. On days 44-58, gilts detected in estrus were inseminated twice, 24 h apart with pooled semen via AI. Blood samples were obtained on days 0, 7, 18 and 42 and analyzed for serum progesterone (P(4)). Bred gilts were slaughtered on days 58-62 of gestation. Ovulation, as determined by serum concentrations of P(4) on day 7 of the experiment, was induced by hCG in 79.5% of treated gilts. Zeranol implants, however, failed to increase (P>0.05) the proportion of gilts available for breeding (treated, 21/39; control, 18/40). Of gilts inseminated on days 44-58, 16/21 treated gilts and 16/18 control gilts were pregnant at slaughter on days 58-62 of gestation. Number of fetuses (7.5 versus 12), fetal weight (83 versus 121 g), fetal length (117 versus 132 mm) and fetal survival (45% versus 78%) were reduced (P<0.001) by Zeranol implants. These data indicate that treatment of peripubertal gilts with a 36 mg Zeranol implant did not increase the proportion of gilts available for breeding while causing deleterious effects upon the fetuses.

Effect of nursing-calf implant timing on growth performance and carcass characteristics.

The objective of this study was to compare pre- and postweaning growth performance, carcass characteristics, and meat quality attributes of calves that did not receive an implant or were implanted early or late in the nursing period. Crossbred steer calves ( = 135) were stratified by birth date and birth weight and randomly assigned to the following implant treatments: control (CON; no preweaning implant), 58 d (EARLY; 36 mg zeranol, administered at an average of 58 ± 13 d of age), and 121 d (LATE; 36 mg zeranol, administered at an average 121 ± 13 d of age). After weaning, steers were blocked by initial feed yard BW to 15 pens (5 pens/treatment and 9 steers/pen). All steers were implanted on d 21 after arrival at the feed yard and again on d 108 of finishing. Steer BW and ultrasound assessment of rib eye area (uREA), rib fat thickness (uRFT), and percent intramuscular fat (uIMF) were collected when implants were administered, at weaning, and on harvest day. Carcass measurements included HCW, rib eye area (REA), 12th-rib fat thickness (FT), and marbling score. Objective color (L*, a*, and b*) was recorded, and a 3.8-cm strip loin section was removed from both sides of each carcass and portioned into 2.54-cm steaks that were aged for 3 or 14 d for analysis of cook loss and Warner-Bratzler shear force (WBSF). The remaining portion of each sample was used for analysis of moisture and crude fat. Steer BW, ADG, and G:F did not differ among treatments ( > 0.05). Steers implanted in the EARLY treatment had a greater ( < 0.05) cumulative DMI than CON but were not different from steers implanted in the LATE treatment. Ultrasound REA and uRFT (averaged across all collection days) did not differ ( > 0.05); however, steers on the CON treatment had a greater ( ≤ 0.05) percent uIMF than EARLY implanted steers, whereas steers receiving the LATE implant were intermediate and not different from the other treatments. Hot carcass weight, REA, FT, USDA yield grade, marbling score, and objective color did not differ ( > 0.05) among treatments. The proportion of steers in each USDA yield and quality grade was similar ( > 0.05) among treatments, and no differences were detected for total carcass value or price per 45.4 kg (hundredweight; > 0.05). Treatment did not influence ( > 0.05) percent cook loss, crude fat, moisture, or WBSF. In conclusion, administering a nursing implant, regardless of timing, did not influence live performance, carcass characteristics, or meat quality of steers fed in this study.

Effects of timing of anabolic implant insertion on growth and immunity of recently weaned beef steers.

We evaluated the effects of timing of estrogenic implant insertion, relative to weaning, on growth performance and measurements of innate and humoral immunity of beef calves. On d -14, Angus × Simmental crossbred steers ( = 48; BW = 217 ± 5 kg; age = 191 ± 3 d) were stratified by BW, age, and cow parity and randomly assigned to receive no implant (NOIP) or 36 mg of zeranol on d -14, 0, or 14, relative to weaning (IP-14, IP0, and IP+14, respectively; 12 steers/treatment). From d -14 to 0, cow-calf pairs remained on a single, tall-fescue pasture with no access to concentrate supplementation. Steers were weaned on d 0, stratified by treatment and BW, and then allocated into 1 of 16 drylot pens to receive daily free-choice access to a corn silage-based diet during the preconditioning phase (d 0 to 56). Steers were vaccinated against infectious bovine rhinotracheitis (IBRV), bovine viral diarrhea virus (BVDV), and on d -27 and 0. From d 56 to 252 (postpreconditioning phase), steers remained in their respective feedlot pens and were provided free-choice access to corn silage-based growing (d 56 to 167) and finishing total mixed rations (d 168 to 252). Body weight on d 0 did not differ among treatments ( ≥ 0.29) but was greater for IP-14 and IP0 than NOIP and IP+14 steers on d 14, 42, and 56 ( ≤ 0.05). Treatment effects were not detected for G:F and DMI from d 0 to 56 ( ≥ 0.34), but ADG from d -14 to 56 was greater for IP-14 compared to NOIP ( ≤ 0.05) and intermediate for IP0 and IP+14 steers. Plasma IGF-1 concentrations were greater for IP-14 than NOIP ( ≤ 0.05) and intermediate for IP0 and IP+14 steers on d -7, 0, 14, and 21. Plasma concentrations of cortisol and haptoglobin and serum titers against BVDV types 1a and 2 did not differ among treatments from d 0 to 56 ( ≥ 0.37). However, serum IBRV titers were greater for IP+14 than NOIP, IP-14, and IP0 steers ( ≤ 0.02). On d 252, BW was greater for IP-14 and IP0 than NOIP steers ( ≤ 0.05) and intermediate for IP+14 steers, but ADG and G:F from d 57 to 252 and carcass characteristics at slaughter did not differ among treatments ( ≥ 0.16). Thus, the 36-mg zeranol implant did not elicit an inflammatory response or affect the overall vaccine response of steers (except for IBRV titers). However, growth of steers during a 56-d preconditioning period was enhanced by administering 36-mg zeranol implant 14 d before weaning, without affecting subsequent postpreconditioning growth and carcass characteristics at slaughter.

Individual and combined effects of deoxynivalenol and α-zearalenol on cell proliferation and steroidogenesis of granulosa cells in cattle.

This study was conducted to evaluate the impact of deoxynivalenol (DON) and zearalenone (ZEA) metabolite, α-zearalenol (α-Zol), on cell proliferation and steroidogenesis of bovine large (LG) follicle granulosa cells (GC). LGGC were obtained from bovine ovarian follicles (8-22 mm) and were cultured for 2 days in medium containing 10% fetal bovine serum followed by 1 or 2 days in serum-free medium without (control) or with treatments. Three different experiments were performed using different dosages of DON and α-Zol and in different combinations and a fourth experiment evaluated estradiol effects on granulosa cell proliferation. DON inhibited progesterone (P4) and estradiol (E2) production at high dose. α-Zol alone and in combination with DON increased cell growth. Estradiol inhibited cell growth indicating α-Zol is not acting as an estrogen agonist. This study demonstrates that α-Zol and DON can impact in vitro GC function, however further studies will be required to better understand the mechanism of action and reproductive effects of Fusarium mycotoxins.

Hormone contents in peripheral tissues after correct and off-label use of growth promoting hormones in cattle: effect of the implant preparations Filaplix-H, Raglo, Synovex-H and Synovex Plus.

Certain hormonal growth promoters are licensed in several beef producing countries outside the European Union (EU). Use in compliance with Good Veterinary Practice is mandatory. As risk assessment of hormone residues in animal tissues up to now has neglected potential off-label use, the present study dealt with two topics: 1) multiple treatment with the implant preparations Finaplix-H (200 mg trenbolone acetate), Ralgro (36 mg zeranol) and Synovex-H (200 mg testosterone propionate plus 20 mg estradiol benzoate) in heifers (1-fold, 3-fold and 10-fold dose), and 2) non-approved treatment of female veal calves (1-fold dose of Synovex-H or Synovex Plus with 200 mg trenbolone acetate plus 28 mg estradiol benzoate). Residues of estradiol-17beta, estradiol-17alpha, estrone and testosterone, trenbolone-17beta, trenbolone-17alpha and trendione or zeranol, respectively, were measured in loin, liver, kidney and peri-renal fat by high performance liquid chromatography/enzyme immunoassay (HPLC/EIA) after liquid-liquid extraction and solid-phase clean-up. The hormone residues in the multiple-dose experiments were dose-dependent and partially exceeded the threshold values: in the liver in one animal after 3-fold dose and in two animals after 10-fold dose of Finaplix-H, and in the liver and kidney after 3-fold and 10-fold dose of Synovex-H. Mean hormone residues in calves were mainly below those of heifers and did not infringe threshold values.

Quantification of rainbow trout (Oncorhynchus mykiss) zona radiata and vitellogenin mRNA levels using real-time PCR after in vivo treatment with estradiol-17 beta or alpha-zearalenol.

Estrogen receptor-mediated induction of zona radiata (ZR) and vitellogenin (VTG) mRNA and protein in rainbow trout (Oncorhynchus mykiss) was compared to assess their utility as biomarkers for exposure to estrogenic compounds. Partial sequences of rainbow trout ZR and beta-actin were cloned by reverse transcriptase polymerase chain reaction (RT-PCR) using degenerate primers based on conserved regions across a number of species. A 549 bp fragment of the rainbow trout ZR-gene showed a high degree of amino acid sequence identity to that of salmon (77%), winter flounder (64%), carp ZP2 (63%) and medaka (61%) ZR-proteins. The 1020 bp beta-actin fragment was approximately 100% identical to sequences from several species. Real-time PCR was used to quantify the induction of ZR-gene and VTG in rainbow trout liver after in vivo exposure to estradiol-17 beta (E(2)) (0.01, 0.1, 1.0 or 10 mg/kg body weight (bw) fish) or alpha-zearalenol (alpha-ZEA) (0.1, 1.0 or 10 mg/kg bw). Real-time PCR and indirect enzyme-linked immunosorbent assay (ELISA) showed that ZR and VTG were induced in both the liver and the plasma after a single injection of E(2) or alpha-ZEA. ZR was more responsive to low levels of E(2) and alpha-ZEA than VTG, and real-time PCR was shown to be more sensitive than the ELISA. Rainbow trout ZR-gene and proteins provide a sensitive biomarker for assessing estrogenic activity.

Testicular toxicity and mutagenicity of steroidal and non-steroidal estrogens in the male mouse.

The mutagenicity and toxicity of diethylstilbestrol (DES), 17 beta-estradiol and zeranol on the male mouse germ cells were investigated with meiotic micronucleus assays in vivo and in vitro, sperm-head abnormality test and morphometry. Further, the developmental effects of DES on testicular morphology were explored. Micronucleus induction was observed at 10(-7) M concentration of DES and 17 beta-estradiol in vitro, but other treatments yielded negative results. The micronucleus assay in vivo revealed a small number of micronuclei in early haploid spermatids 17 days after a single subcutaneous injection of DES 50 mg/kg, whereas estradiol and zeranol gave negative results. The sperm-head abnormality rates were significantly elevated 5 weeks after treatments with high doses of DES, 17 beta-estradiol and zeranol, and testicular morphometry revealed transient changes in the volume densities of testicular tissue components. Prenatal and neonatal estrogen administration resulted in permanent alterations in seminiferous epithelium and dilatation of the rete testis, but did not affect micronucleus or sperm-head abnormality rates. The mutagenicity and toxicity of hormones in the mouse testis paralleled the hormonal activity of these compounds. Early estrogenization was the most sensitive toxicity test, followed by in vitro meiotic micronucleus induction, whereas the sperm-head abnormality assay and morphological analysis did not reveal subtle changes.

Metabolic profiles of the mycotoxin zearalenone and of the growth promoter zeranol in urine, liver, and muscle of heifers.

A group of five heifers were fed for 84 days with 2 kg of zearalenone-contaminated oats (1370 microg/kg) resulting in an average daily intake of 2740 microg of zearalenone per animal. In a parallel experiment five heifers were implanted with two 25 mg zeranol pellets, one at the beginning of the study and one after 42 days, and fed with 2 kg of "blank" control oats (79 microg/kg, daily intake = 158 microg). A third group of five animals were also fed with 2 kg of "blank" oats and served as control. Urine samples of all animals were collected every 5-6 days during the whole period of the study. Animals of all three groups were killed 84 days after the beginning of the feeding study. Tissue samples (back, femoral region, liver, and residues of implanted pellets) were taken during post-mortem investigations. The content of zearalenone and zeranol and their metabolites in urine and tissue samples was established by an analytical method combining solid-phase extraction and high-performance liquid chromatography-tandem mass spectrometry. Urinary excretion rates of zeralenone and zeranol were calculated from these results.

Hormone secretory patterns, pituitary characteristics and selected blood metabolites in feedlot steers implanted with growth stimulants.

Twelve Charolais-crossbred steers (256 kg) received one of three treatments: nonimplanted controls (C), implanted initially and at 84 days with 36 mg zeranol (Ralgro, R) and implanted initially and at 84 days with 200 mg of progesterone and 20 mg of estradiol benzoate (Synovex-S,S). All steers were fed a corn-based diet (calculated metabolizable energy 2.89 Mcal/kg dry matter) ad libitum. In a parallel comparative slaughter trial, rates of empty body protein accretion were increased 14% in R and 24% in S steers (P less than .01). R and S steers in the present study had heavier pituitary weights (P less than .001), more pituitary growth hormone content (P less than .04) and more pituitary weight/unit live weight (P less than .05) than did C steers. Cattle implanted with R or S exhibited an increased growth hormone (GH) secretory response to a pituitary challenge with thyrotropin releasing hormone (TRH). Plasma insulin profiles were not significantly altered, but tended to be greater for steers given implants. Overall 9-hr GH secretory profiles were not affected by implantation. Plasma urea N at 94 days post-implantation was decreased (P less than .01) by implantation. Plasma glucose was increased (P less than .04) at both 94 and 199 days in R and S vs C steers. Overall mean and total (integrated area) plasma GH, as well as secretory profile components (baseline mean, amplitude of secretory spikes) were negatively correlated with body weight and size on days 94 and 199. Overall mean, baseline and integrated area of plasma insulin on days 94 and 199 were positively related to body weight and size. Thus positive protein anabolic growth responses from implantation (parallel comparative slaughter trial) were coupled with increased pituitary GH content and little change in circulating plasma GH concentrations between implanted and control steers. This may suggest that changes in tissue sensitivity, an increased plasma clearance rate of GH and/or a direct effect on target tissues may be involved in the improved growth performance of cattle implanted with R or S.

Measurement of zeranol in plasma from three blood vessels in steers implanted with zeranol.

Zeranol (Z) is a widely used growth promotant; however, plasma Z profiles in cattle implanted with Z have not been characterized. This study was conducted to determine bovine plasma Z profiles. In Exp. 1, four steers (BW = 284.8 +/- 5.6 kg) were implanted with 108 mg of Z (Ralgro). To determine the effect of sampling site on plasma Z concentrations, blood was sampled by venipuncture from the maxillary vein ipsilateral (IMV) to the ear in which Z was implanted and from the ipsilateral (IJV) and contralateral (CJV) jugular veins of each steer. Samples were collected on d 1, 4, 6, 8, 11, and 13 after implantation and Z was assayed by RIA. There was an effect of sampling site (P < .01). The overall mean plasma Z concentrations and 95% confidence intervals (CI) for each vessel were 282 (CI: 172 to 463), 135 (CI: 85 to 215), and 67 (CI: 42 to 106) pg/mL for the IMV, IJV, and CJV, respectively. Plasma Z concentration was higher (P < .05) in IMV than in IJV and higher (P < .05) in IJV than in CJV. In Exp. 2, nine steers (BW = 316.7 +/- 10.0 kg) were implanted with 108 mg of Z and IMV blood was collected on d 0, 1, 3, 7, 10, 14, 17, 21, 28, 35, 42, 56, 63, 73, and 91 after implantation. Day affected plasma Z concentration (P < .01); plasma Z was elevated above preimplantation levels for 91 d (P < .05).(ABSTRACT TRUNCATED AT 250 WORDS)

Blood and serum components and organ weights in steers, bulls and zeranol-implanted bulls.

To investigate certain physiological aspects of the mode of action of zeranol or Ralgro on growth, behavior and carcass quality of young bulls, concentrations of 19 blood components and weights of eight organs were determined. Experimental animals consisted of 36 untreated steers, 36 untreated bulls, 36 bulls implanted with zeranol at 3 mo of age and subsequently at 5, 8 and 10 mo and 36 bulls implanted with zeranol at 6 mo of age and subsequently at 9 and 11 mo. In addition, half of the animals in each group were subjected to moderate pre-slaughter stress (mixing and trucking 160 km); the other half was subjected to minimum pre-slaughter stress (no mixing and 4 km transport). Concentrations of cortisol, urea nitrogen and albumin in serum were higher (P less than .01) and those of glutamic oxaloacetic transaminase (GOT), lactate dehydrogenase (LDH), alkaline phosphatase (AP) and creatinine were lower (P less than .05) in steers than in intact males. Concentrations of GOT, LDH, and creatinine were higher (P less than .05) in implanted than those in control males. Pre-slaughter stress had a significant effect on several traits measured in blood or serum. Thyroid glands were smaller (P less than .01) in steers than in control and implanted males. Testes were smaller (P less than .01) in the zeranol-implanted than in untreated males. Results indicate that zeranol had only a minor effect on the 19 blood components studied, but it did reduce testicle size. Castration had a major impact on several of the blood components. Pre-slaughter management had a significant effect on several blood components.

Effects of animal and supplement characteristics on average daily gain of grazing beef cattle.

Effects of animal gender and age, use of a growth stimulant, and supplementation with grain alone or grain plus other substances on ADG by growing beef cattle grazing bermudagrass paddocks with sod-seeded rye, wheat, and ryegrass were determined. Two grazing experiments (Exp. 1: late winter through mid-spring; Exp. 2: late spring through mid-summer) were conducted. Experiment 1 used 96, 12- to 13-mo-old Simmental-cross calves (heifers, 240 kg; steers, 272 kg), half of which were implanted with zeranol. Within each implant treatment, cattle received no supplement or .5% BW (DM) of ground corn alone or plus a mix of protein meals, zinc sulfate, thiamin-HCl, or salt. Daily gain was higher (P less than .05) with than without supplementation and was similar (P greater than .10) among supplement treatments. In Exp. 2, 96 crossbred beef steers, approximately 7 (230 kg) or 15 mo old (250 kg), were not supplemented (control) or received .5% BW (DM) of ground corn on d 1 to 84 (C-C), corn plus a protein meal mix on d 1 to 84 (CP-CP), corn on d 43 to 84 (O-C), corn plus the protein meal mix on d 43 to 84 (O-CP), or corn on d 1 to 42 and corn plus the protein meal mix on d 43 to 84 (C-CP). Daily gain on d 1 to 84 was affected (P less than .05) by supplement, age, implant, and the supplement x implant interaction (nonimplanted: .37, .56, .68, .40, .49, and .49; implanted: .37, .62, .54, .49, .70, and .71 kg for control, C-C, CP-CP, O-C, O-CP, and C-CP, respectively).

Effect of pre- and postweaning zeranol implant on steer calf performance.

One hundred ninety-five steer calves were assigned to five zeranol implant treatment (trial 1). Treatments were no implants (0000), two implants during the finishing period (00XX), three implants during growing and finishing periods (0XXX), one implant at 1 to 2 mo of age during the suckling period and two during the finishing period (X0XX) or four implants (XXXX). The growing period implant was administered at weaning. Weaning weights (211 vs 208 kg) of implanted and nonimplanted suckling calves were not different (P greater than .05). Calves implanted at weaning, before shipment to the feedlot, had greater (P less than .05) weight loss in shipment than nonimplanted calves. In the feedlot, finishing-period daily gains of steers implanted in the growing and finishing period (0XXX) were greater (P less than .05) than gains of steers that had received a suckling period implant (X0XX and XXXX). Nonimplanted steer gains were less (P less than .05) than gains of steers from the other four treatment groups. Postweaning daily gains and final weights were 1.18 and 517 (0000), 1.26 and 533 (00XX), 1.32 and 551 (0XXX), 1.26 and 540 (X0XX) and 1.25 and 533 kg (XXXX), respectively. Gains and final weights of nonimplanted steers were less (P less than .05) than gains of steers implanted only in the feedlot growing and finishing periods (0XXX). In a second trial, 82 steers were assigned either to a 0XXX or XXXX implant scheme. Weaning weights were 11 kg greater (P less than .05) for the implanted steers.(ABSTRACT TRUNCATED AT 250 WORDS)

Effect of sequential implanting with zeranol on steer lifetime performance.

Three trials involving 513 exotic crossbred steers were conducted to determine the effect of zeranol implanting in the suckling and growing phases on subsequent feedlot performance and carcass characteristics. Treatments were 1) unimplanted control, 0000; 2) implanted twice in the finishing phase, 00II; 3) implanted in the growing phase and twice in the finishing phase, 0III; 4) implanted in the suckling phase and twice in the finishing phase, I0II; 5) implanted in the suckling and growing phases with a single implant in the finishing phase, III0; and 6) implanted in the suckling and growing phases and twice in the finishing phase, IIII. Implanting in the suckling period did not significantly affect preweaning gain. Implanting in the growing period produced a treatment x trial interaction (P less than .05), but zeranol increased gains by an average of 8.4% over the three trials. Growing period gain was not influenced by implanting during suckling. Implanting twice during the finishing period increased gain (P less than .05) over unimplanted and III0 steers. Finishing gain was not influenced by previous suckling and(or) growing implant treatment. Lifetime ADG of steers was increased (P less than .05) by all implant treatments compared with unimplanted controls. Zeranol tended (P = .14) to improve feed conversion in the finishing phase. All implant treatments increased hot carcass weight (P less than .05), and all but III0 reduced fat deposition, as indicated by lower quality grade (P less than .05). Other carcass characteristics were not significantly affected by treatment. These trials demonstrated that implanting in the suckling and(or) growing phases of production did not reduce performance in the finishing phase.

Effects of nutrition, sex of calf and breed type on response to zeranol: preweaning growth.

An experiment was conducted to evaluate the effects of breed, sex and plane of nutrition on the growth response to zeranol in Angus and crossbred calves prior to weaning. Eighty-eight heifers and 118 steers received either a high or low plane of nutrition using a first and last grazing technique. Half of the calves in each nutrition group received a zeranol implant (36 mg) at an average age of 3.4 mo. Both zeranol and the higher level of nutrition increased (P less than .001) growth rate prior to weaning (7.4 mo of age). Zeranol did not affect hip height at weaning (P greater than .1), but calves on the higher plane of nutrition were taller (P less than .01) than calves on the lower plane of nutrition. The zeranol x nutrition interaction was not significant (P greater than .1) for growth rate or hip height. Steers grew faster (P less than .01) preweaning and were taller (P less than .01) at weaning than heifers. Crossbred calves gained more rapidly (P less than .001) preweaning and were taller (P less than .001) at weaning than Angus calves were. Neither sex nor breed interacted with zeranol to influence any of the traits examined. Based on these results we conclude that preweaning growth was affected by zeranol and this effect was consistent across sexes, breeds and planes of nutrition tested.

Time of zeranol implantation on growth, reproduction and calving of beef heifers.

Zeranol implants were administered to 250 crossbred heifer calves at 1, 6 or 9 mo of age to evaluate growth, reproduction and calving performance. Heifers were assigned to eight treatment groups with 25 animals per group. Two additional groups of 25 heifers each were used to study the effects of multiple implants at two levels of nutrition on heifer performance. Implants at 1 mo of age (branding) increased heifer weights at 6 mo of age (weaning) by 5 kg (P = .08). Heifers receiving a combination of two implants gained faster (P less than .05) from weaning to breeding (6 to 13 mo) than controls or heifers implanted three times. Implants at either 6 or 9 mo increased (P less than .05) precalving pelvic areas (247 vs 241 cm2 and 248 vs 240 cm2 over controls, respectively). Implants did not affect the percent of heifers reaching puberty prior to breeding season. Conception rates in 62 d of breeding were comparable for implanted and control heifers (93 vs 96%), with the exception of heifers receiving implants at both 1 and 6 mo of age (56%). Calf birth weight, dystocia score, cow rebreeding rate and calf weaning weight were not affected by implant treatments. Heifers that received three implants and were fed at a high nutritional level (gained .62 vs .49 kg/d for regular level after weaning) tended (P greater than .10) to reach puberty at a higher rate prior to breeding and to have a higher total conception rate than implanted heifers on the regular nutrition level.